ArticleAdvances in hematology2015

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

Keith L Davis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.